Spyre Therapeutics To Host Conference Call To Report SPY001 Part A Induction Topline Results From SKYLINE Trial In Moderate-To-Severe Ulcerative Colitis Patients On April 13, 2026

(MENAFN- GlobeNewsWire - Nasdaq) WALTHAM, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases, today announced it will report SPY001 Part A induction topline results from the SKYLINE trial in moderate-to-severely active ulcerative colitis patients on Monday, April 13, 2026. Following the announcement, the Company will host a conference call and webcast at 8:00am ET on Monday April 13, 2026 to discuss the results.

To access the live and archived webcast, please visit the Investor Relations page of Spyre's website at .

About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.

For more information, visit Spyre's website at .

For Investors:
Eric McIntyre, Spyre Therapeutics
SVP of Finance and Investor Relations
...

For Media:
Josie Butler, 1AB
josie@1abmedia

MENAFN10042026004107003653ID1110968476